AVIR Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Cash Position: Atea Pharmaceuticals reported cash and marketable securities of $219.5 million as of June 30, 2026, with a cash runway projected to extend through 2027.

R&D Expenses: Increased due to higher external spending related to HCV Phase III trials and HEV preclinical activities, partially offset by lower internal expenses.

G&A Expenses: Decreased compared to the prior year, attributed to lower salaries and stock-based compensation.

2Strategic Updates and Business Highlights

CBEYOND Trial: The Phase 3 trial for bemrusasvir (BEM/RZR) demonstrated positive top-line results, meeting both primary and secondary endpoints, showing statistical non-inferiority to the current standard of care, Epclusa.

C FORWARD Trial: Fully enrolled with over 880 patients, results expected in early Q1 2027. This trial aims to provide complementary efficacy data across a broader range of hepatitis C genotypes.

Hepatitis E Program: Initiated a Phase 1 clinical trial for AT-587, a potential first-in-class treatment for hepatitis E, reflecting Atea's commitment to expanding its antiviral pipeline.

Market Dynamics: The company noted a growing HCV-infected population in the U.S., with an addressable market potentially expanding to $2.5 billion annually due to unmet treatment needs.

3Forward Guidance and Outlook

NDA Submission: Anticipated for Q2 2027, pending positive results from the C FORWARD trial.

Commercial Readiness: Atea is preparing for a potential launch of BEM/RZR in mid-2028, with plans for a focused specialty sales force to reach high-volume prescribers.

Revenue Potential: Projected peak annual U.S. net revenue potential for BEM/RZR is estimated to exceed $700 million, driven by a widening gap between infections and cures.

4Bad News, Challenges, or Points of Concern

Market Perception: There is a perception of a declining market for HCV therapies, despite the growing number of untreated patients.

Regulatory Risks: The company faces uncertainties related to regulatory approvals and market access for its new therapies.

Competitive Landscape: Pricing reforms and legislative changes (e.g., Medicare Part D, 340B) are reshaping the competitive landscape, which could impact market dynamics and pricing strategies.

5Notable Q&A Insights

Labeling and Mechanism of Action: Questions arose regarding how the new mechanism of action would be incorporated into the drug label. Atea plans to share data with the FDA in early 2027.

Test and Treat Model: KOLs expressed interest in a test-and-treat model, which Atea is positioning its therapies to support, emphasizing the convenience of blister pack dosing.

C FORWARD Trial Comparisons: Analysts inquired about the comparability of baseline characteristics between C BEYOND and C FORWARD trials, with expectations of a more compliant patient population in the latter.

Pricing Dynamics: Discussion on how recent pricing reforms could affect the competitive landscape, with Atea noting that the impact may not be as severe as anticipated due to the unique pricing structure of HCV therapies. This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and notable insights from the Q&A, providing a balanced view of Atea Pharmaceuticals' current position and future outlook.